Education
09 / 2004 – 07 / 2006 Movie Director School, ANT1 Movie School Athens, Greece, Degree “Television Director”, grade point average: B
09 / 2006 – 08 / 2008 Medical School, Semmelweis University Budapest, Hungary, Medical preliminary examination (Physikum), grade point average: A
10 / 2008 – 05 / 2013 Medical School, Albert-Ludwigs-Universität Freiburg, Germany, State examination in medicine, grade point average: A
02/ 2009 – 02/2012 Institute of Pharamcology and Toxicology I, Albert-Ludwigs-Universität Freiburg, Germany, Doctoral thesis, grade: summa cum laude
05 / 2018 Basic and advanced course in German drug law and GCP, Clinical Trials Unit, Medical Center - University of Freiburg
01 / 2019 Board certification: Radiotherapy and Radiation Oncology
03 / 2020 Medical Center University of Freiburg, Department of Radiation Oncology, Germany, Habilitation (Postdoctoral lecture qualification)
09 / 21 – 08 / 23 MHBA, Friedrich Alexander University, Nuernberg, Germany
07 / 2022 Completion of ISO 9001:2015 training, Nicosia, Cyprus
Professional Career
09 / 2013 – 01 / 2019 Medical Center University of Freiburg, Department of Radiation Oncology, Germany, Residency
07 / 2017 – 07 / 2020 Bertha-Ottenstein programme, Medical Center, University of Freiburg, Germany, Clinician Scientist
Since 06 / 2019 Medical Center University of Freiburg, Department of Radiation Oncology, Germany, Consultant
01 / 2021 – 12 / 2022 Bertha-Ottenstein programme, Medical Center, University of Freiburg, Germany, Advanced Clinician Scientist
01 / 2021 – 12 / 2021 Head of the section “Interventional Radiation Oncology”, Medical Center University of Freiburg, Department of Radiation Oncology, Germany
Since 01 / 2022 Medical Center University of Freiburg, Department of Radiation Oncology, Germany, Prostate cancer research group leader
Since 01 / 2022 German Medical Institute, Limassol, Cyprus, Vice Medical Director
Professional Memberships and Distinctions
2010 Sanofi-Aventis poster prize, Annual meeting of the German Society of Pharmacology and Toxicology 2010, Mainz, Germany
2017 Poster prize, Annual meeting of the German Society of Radiation Oncology (DEGRO) 2017, Berlin, Germany
2019 Poster prize, Uro-Oncological Symposium 2019, Magdeburg, Germany
2020 Invited member of the German expert panel for prostate cancer of the German Society of Radiation Oncology (DEGRO)
2020 Herman-Holthusen Award, German Society of Radiation Oncology (DEGRO)
2021 Invited member of the ESTRO-ACROP guideline committee for prostate cancer
2021 Best Abstract, EMUC congress 2021, Athens, Greece
2023 Annual ARO study price for the HypoFocal-SBRT study from the German Cancer Foundation
2023 Invited member of the ESTRO focus group “Urology”
Professional experience:
04.2009 – 04.2013: Resident in the Department for Radiation Oncology, Klinikum Offenbach
05.2013 – 12. 2015: Senior physician in the Department for Radiation Oncology, Klinikum Offenbach
Dr. Selime Aydogdu is a specialist in pediatric hematology and oncology. She is known for her work in improving early cancer detection in children. Dr. Aydogdu has given many presentations and led discussions on recognizing early cancer symptoms. Her efforts have raised awareness in her field.
Her work has helped achieve better diagnostic results and higher survival rates for children. Dr. Aydogdu is dedicated to education and advocacy. She is a respected member of the pediatric oncology community.
Activities • Prevention, research and early diagnosis of cancer • Palliative care in cancer • Cytotoxic chemotherapy • Hormontherapy • Targeted treatment • Immunotherapy Education • 2004 -2010 - Istanbul University, Istanbul faculty of medicine • 2011-2015 - Istanbul University, Istanbul faculty of medicine, internal medicine specialist • 2013-2014 - Cleveland Clinic Endocrinology Department, research associate • 2016-2019 Bezmiâlem Foundation University Medical Oncology Subdivision • Dissertation: Prognostic value of absolute monocyte count in patients with mantle cell lymphoma. • Subdivision Dissertation: An effect of adjuvant chemotherapy on lipid profile and anthropometric parameters in patients with breast and colon cancer. Publications • Circulating Thyroid-Stimulating Hormone Receptor Messenger RNA as a Marker of Tumor Aggressiveness in Patients with Papillary Thyroid Microcarcinoma. Aliyev A, Gupta M, et al. Endocr 18. • The utility of peripheral thyrotropin receptor mRNA in the management of differentiated thyroid cancer. • Aliyev A, Soundararajan S, Bucak E et al. Surgery. • Diagnostic accuracy of circulating thyrotropin receptor messenger RNA combined with neck ultrasonography in patients with Bethesda III-V thyroid cytology. Aliyev A, Patel J, Brainard J, et al. Surgery.2016 Jan;159(1):113-7. doi: 10.1016/j.surg.2015.06.063. Epub 2015 Oct 9. • Role of Urotensin-2 in 5-Fluorouracil-Related Arterial Vasoconstriction in Cancer Patients. Seker M, Aliyev A, et al. Oncol Res Treat. Epub 2018 Aug 20. • Pertuzumab, trastuzumab and taxane-based treatment for visceral organ metastatic, trastuzumab-naive breast cancer: real-life practice outcomes. Esin E, Oksuzoglu B, Bilici A, Aliyev A. Cancer Chemother Pharmacol.2019 Jan; Epub 2018 Oct 30. • Usefulness of serum M30 and M65 levels to predict response to neoadjuvant chemotherapy in patients with breast cancer. Turk HM, Aliyev A, Celik RS. Curr Probl Cancer.2019 Jul 29. pii: currproblcancer.2019.06.009. • Prognostic impact of primary tumor location on survival in metastatic colorectal cancer patients: A single center experience. Tarik Demir, Murat Araz, Altay Aliyev. Medicine Science International Medicine Journal. • Oral presentations
Dr. Jesus Soberino is an oncologist at Vall d’Hebron University Hospital and the Vall d’Hebron Institute of Oncology (VHIO). He specializes in breast cancer and melanoma. Dr. Soberino has led many phase 1–3 clinical trials. His work has helped approve important drugs, including CDK4/6 inhibitors for metastatic breast cancer and immunotherapies for melanoma.
His areas of expertise include endocrine therapy, managing hormone resistance, and developing new immunotherapies. Dr. Soberino is known for his patient-centered care. He actively collaborates in research to improve cancer treatment. He is accredited by VHIO and is a key member of the Breast Cancer and Melanoma Units.
Dr. Enriqueta Felip is an expert in thoracic oncology. She specializes in lung cancer care and clinical trials. She earned her medical degree and PhD from UAB. Dr. Felip has led research on improving chemotherapy, developing new therapies, using immunotherapy, and understanding resistance to targeted treatments.
She served as a board member of the IASLC from 2017 to 2021 and was Vice-President of SEOM from 2019 to 2021. In 2015, she received the first ESMO Women for Oncology Award. Dr. Felip has written many peer-reviewed articles and book chapters. She is known for her leadership in international oncology societies and clinical research.
Dr. Francesc Graus is a neurologist with expertise in paraneoplastic neurological syndromes, gliomas, and primary brain lymphomas. He established the first strict diagnostic criteria for paraneoplastic syndromes. He also identified important antibodies that are now used in diagnosis. His research showed the link between tumors and autoimmune neurological attacks.
Dr. Graus earned his MD and PhD from Universitat Autònoma de Barcelona. He completed his neurology residency in Barcelona and a neuro-oncology fellowship at Memorial Sloan-Kettering Cancer Center. He is an Emeritus investigator at IDIBAPS. He founded and served as president of the European Association of Neuro-Oncology. He is also the former chief of neurology at Hospital Clinic Barcelona.
Dr. Francesc Cobo Valien graduated from the Faculty of Medicine of the University of Barcelona in 1990.
He received his specialization in oncohematology at the Hospital Clínic de Barcelona in 1995. He combined medical practice and research activities in the period 1996-2002.
He received his Doctor of Medicine degree from the University of Barcelona in 2002.
Dr. Kobo continues his research and has been awarded grants:
•Interdepartmental Commission for Innovation of the Generalitat de Catalunya
•Scholarship Fund Universitaria Agustí Pedro i Pons
•Farreras Valentí & Schering Plough School of Hematology Scholarship
•Award for the best report at the Council of the Spanish Hematology Association
•Grant from the Catalan Society of Hematology
Specialization:
•Lymphoma
•Acute leukemia
•Chronic leukemia
•Autoimmune pancytopenia
Dr. Balaña received her medical degree from the Central University of Barcelona and completed her residency in medical oncology at one of the best public hospitals in Spain, Vall d'Hebrón Hospital.
She was a leading specialist in the treatment of brain tumors at the Institute of Oncology of Catalonia, a founding member and current president of the Spanish Neuro oncology Research Group (GEINO), and a member of the scientific committee of the European Association for Neuro-Oncology.
He is the recipient of prestigious research grants in the field of brain tumors.
Dr. Balaña is also a member of the European Society of Medical Oncology and the author of modern European protocols for the treatment of brain tumors, as well as the protocols of the Spanish Society of Medical Oncology (SEOM).
Dr. Balaña has published over 400 articles, books and scientific papers at national and international conferences.
He is the author of articles in prestigious scientific publications such as:
Lancet Oncology;
Nature Reviews in Clinical Oncology;
Clinical Cancer Research and others.
Dr. Rahib Hasanov is a medical oncologist. He graduated from Istanbul University Cerrahpaşa Faculty of Medicine (1999–2005). He completed an internal medicine residency (2009–2013) and a medical oncology fellowship at Marmara University (2015–2018). He also completed an observership at Houston Methodist Hospital (2006–2007).
He focuses on personalized oncology. His treatments include immunotherapy, targeted therapy, and novel agents. His clinical interests include gastrointestinal, breast, lung, and genitourinary cancers.
He attends national and international conferences. He welcomes patients from Turkey, Azerbaijan, Montenegro, Georgia, Uzbekistan, the Middle East, Europe, and the United States.
Profesor Ari Rafael — direktur layanan Onkologi Translasional dan peneliti di departemen penelitian klinis kanker di Pusat Medis Suraski (Ichilov, Tel Aviv). Pasien menghargai pendekatannya yang individual dan perhatian terhadap kebutuhan setiap individu.
Kualifikasi dan nilai bagi pasien:
Memimpin rumah sakit onkologi siang hari dan mengarahkan proyek-proyek kedokteran genom nasional. Hal ini memastikan akses ke penelitian terkini.
Bekerja sebagai penyelidik sub-utama dan penyelidik utama dalam banyak uji klinis fase I–III, termasuk suntikan intratumoral mRNA dan obat-obatan virus. Pasien mendapatkan kesempatan untuk berpartisipasi dalam metode pengobatan inovatif.
Memiliki pengalaman internasional di AS dan Inggris — menjamin penerapan standar dunia dan protokol canggih.
Anggota organisasi internasional (ESMO, IASLC, ISLB, ISCORT, Asosiasi Medis Israel). Menggunakan standar pengobatan modern dan berpartisipasi dalam penelitian global.
Secara rutin meningkatkan kualifikasi dan mengikuti pelatihan sesuai standar praktik klinis internasional, termasuk ICH GCP R2, Panduan MOH Israel, serta kursus terbaru tentang persetujuan yang diinformasikan, penanganan efek samping, dan keselamatan pasien.
Pasien menghargai Profesor Rafael atas pilihan rencana pengobatan yang tepat, penerapan inovasi, dan perhatian yang mendetail, yang memberikan rasa percaya dan aman pada setiap tahap terapi.
Prof. Dr. Sezer Sağlam is a medical oncologist at Gayrettepe Florence Nightingale Hospital. He specializes in gastrointestinal and breast cancers. He has contributed to cancer care through research, especially with his study on the best timing for surgery after neoadjuvant therapy in rectal cancer. This work has influenced global treatment protocols.
Dr. Sağlam has led clinical trials in targeted therapies and precision medicine. His research on liver-transplanted patients with hepatocellular carcinoma was nominated for the 2024 International Best Researcher Award. He is a member of ASCO, ESMO, and ENET. Dr. Sağlam provides personalized and evidence-based oncology care.
Associate Professor Dr. Yusuf AÇIKGÖZ
Specialization: Medical Oncology
Education:
Professional Experience:
Clinical Trials, Courses, Certifications:
Clinical Trials:
Courses:
Certifications:
Memberships:
Dr. Dror Levin is a senior pediatrician and director of the blood disorder and bone cancer (sarcoma) treatment departments at Children's Hospital "Dana" and Medical Center "Sourasky" respectively. He is a specialist in pediatric medicine, hematology, and oncology, with additional experience studying abroad at the Rizzoli Orthopaedic Institute in Italy.
Dr. Irina Stepfansky is an oncologist and internal medicine specialist at Sourasky Medical Center. She has more than 25 years of clinical experience. Since 2015, she has directed the Oncology Hospitalization department. Dr. Stepfansky earned her medical degree from Grodno University in Belarus. She completed advanced oncology training at Tel Aviv Medical Center.
Dr. Stepfansky has been licensed in Israel since 2000. She has led and participated in many phase I-III oncology clinical trials. Her work has helped improve cancer care and patient outcomes. She is recognized for her expertise in both internal medicine and oncology. Dr. Stepfansky has a strong record in research and clinical leadership.
Dr. Michael Shapira is a specialist in Bone Marrow Transplantation with over 20 years of experience. He graduated from the Hebrew University Medical School in 1999. He completed his training in internal medicine at Hadassah Medical Center.
Dr. Shapira is a senior physician in the Bone Marrow Transplantation department at Hadassah. He has played a key role in many successful transplants and has helped maintain high patient survival rates. He is known for his clinical skills and commitment to improving transplantation medicine.
Coping with gastrointestinal and lung cancer without chemotherapy. Specialists at the Tel Aviv Sourasky Clinic (Ichilov) use an ultra-modern innovative method to combat neuroendocrine tumors. It is based on radionuclide therapy with the radioisotope Lutetium 177 (Lutetium-177). This innovation is a real breakthrough in oncotherapy, because in recent decades the number of cases of this type of cancer has been rapidly growing.
This method is completely new in the world. Today it exists only in Israel, Germany and Sweden.
Its essence is in the use of a new radiopharmaceutical - Lutetium 177 PRRT. The drug is administered intravenously at intervals of 7-8 weeks. With the help of Lutetium, cancer cells are destroyed selectively, without affecting healthy tissues of the body. That is, this method of treatment can literally be called "local radiation therapy". In addition, the drug does not have a toxic effect on the bone marrow and kidneys, destroying the tumor from the inside.
In addition, the use of this method allows patients to avoid severe side effects of chemotherapy, such as vomiting, nausea, pain, alopecia, weakness. It is also important that the treatment is carried out by a special group of medical specialists. Among them: leading doctors, nurses and medical physicists!
All of them work under the supervision of Dr. Inna Ospovat, a leading specialist in the nuclear therapy department at the Ichilov Clinic.
Education
2000-1994 Faculty of Medicine in Vitebsk, Belarus.
Specialization
2003 - 2011 - specialization in oncology and radiation therapy at the Hadassah University Hospital in Jerusalem.
Recognized experience
Oncology and radiation therapy
Additional education
2015 - PMH University Hospital (Totonto) Childhood irradiation and head and neck tumors
Attending conferences
About 10 presentations at medical conferences
Trade union membership